B cell-activating factor (BAFF), a well-known tolerance checkpoint, is significantly elevated in the serum of autoimmune disease patients, and its neutralizing antibody, belimumab, is a widely used biologic agent for the treatment of lupus nephritis [135–138]. This evidence concerns the gene TNFSF13B and lupus nephritis.